Neuroendocrine cancers are not a single biological entity. Tumor origin, differentiation, grade, receptor expression, previous treatment, and molecular features can all shape a research question. A result in poorly differentiated neuroendocrine carcinoma should not automatically be applied to a well-differentiated pancreatic NET. Precision research begins by defining the disease and the population clearly. [1]

Molecular profiling can add information. Biomarker testing examines features such as genes, proteins, or other molecules that may help identify treatment options or clinical trials. But a molecular finding is not itself a treatment plan. Testing may reveal no actionable target, a finding with uncertain significance, or a target for which the available drug does not work in that clinical setting. Different cancer cells can also carry different features, and those features may change over time. [2]

Immunotherapy illustrates why these distinctions matter. In the phase II KEYNOTE-158 NET cohort, pembrolizumab showed limited antitumor activity in previously treated, advanced, well-differentiated NETs. This finding supports careful investigation rather than broad claims that checkpoint inhibitors are effective across NETs. [3]

At the same time, certain biomarker-defined cancers can qualify for treatments based on molecular characteristics rather than their organ of origin. These tissue-agnostic indications have specific eligibility requirements. Their existence does not mean that most NETs carry the relevant biomarkers or that every qualifying patient will respond. [4]

The institute’s prospective interest is in research that connects biological insight to decisions that matter: selecting a population, identifying a credible target, measuring a response, and explaining resistance. Strong proposals should state what is known, what remains uncertain, and how the study could resolve that uncertainty.

Translation into a human trial requires more than an attractive mechanism. Clinical research follows a protocol, evaluates safety, and uses oversight and informed consent to protect participants. Participation can advance knowledge, but an investigational intervention may not provide personal benefit. [5]

Our standard is clear: use molecular information to formulate better questions, then test those questions with methods capable of producing trustworthy answers.